期刊文献+

A1500E突变对血管性血友病因子的ADAMTS13依赖性水解的影响

Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13
原文传递
导出
摘要 目的研究血管性血友病因子(VWF)A1500E突变体对金属蛋白酶ADAMTS13敏感性的改变,为VWF—A1500E突变导致2A型血管性血友病(VWD)的发病机制提供直接依据。方法将野生型VWF质粒和A1500E突变体VWF质粒分别瞬时转染HeLa细胞,收集并浓缩培养上清,分别用重组人ADAMTS13(rADAMTS13)进行水解,然后通过十二烷基硫酸钠-琼脂糖凝胶电泳进行VWF多聚体分析,观察与野生型VWF相比,A1500E突变体VWF对ADAMTS13的敏感性有无改变。结果体外表达研究结果显示WT—VWF和A1500E突变体VWF的表达上清中VWF:舷的平均含量分别为1.10U/ml和0.78U/ml,突变体细胞裂解液中的VWF:Ag表达量为野生型的90.6%,两者差异均无统计学意义(P〉0.05)。VWF多聚体电泳显示突变体VWF与WT—VWF的多聚体分布亦无明显差别。在无尿素和盐酸胍等变性剂的静态条件下,rADAMTS13即可对A1500E突变体VWF进行有效地水解,VWF多聚体分析显示大中分子量VWF多聚体明显减少和小分子量VWF多聚体明显增多;相反,野生型VWF在非变性条件下则无被rADAMTS13水解的证据。结论A1500E突变导致突变体VWF对ADAMTS13的敏感性异常性增高,符合第二组2A型VWD的突变特点。 Objective To investigate the susceptibility of yon Willebrand factor (VWF) type 2A mutant A1500E to proteolysis by metalloprotease ADAMTS13 and to provide the direct supports for the pathogenesis of VWF mutation A1500E responsible for yon Willebrand disease (VWD) type 2A. Methods Recombinant wild-type VWF (WT-VWF) and A1500E mutant VWF transiently expressed on transfected HeLa cell lines. Expression media were collected and concentrated, then cleaved directly by recombinant AD- AMTS13 (rADAMTS13). Compared with WT-VWF, the susceptibility of A1500E mutant VWF to proteolysis by ADAMTS13 was analyzed using SDS-agarose gel VWF multimers analysis. Results In vitro the expression of VWF: Ag in the supernatants of WT-VWF and A1500E mutant VWF were 1. l0 U/ml and 0.78 U/ml, respectively, while VWF: Ag in cells lysates of A1500E mutant VWF was 90.6% of that of WT-VWF. The SDS-agarose gel VWF multimers analysis showed that there were no differences between WT-VWF and A1500E mutant VWF. The A1500E mutant VWF could be efficiently cleaved by ADAMTS13 under static condition without denaturants such as urea and guanidine HC1. VWF multimeric analysis showed that high and intermediate molecular weight multimers dramatically decreased while low molecular weight muhimers obvious- ly increased. Conversely, WT-VWF could not be cleaved by ADAMTS13 under the same condition. Conclusion The A1500E mutation resulted in VWF more susceptible to ADAMTS13-dependent proteolysis, which belonged to VWD type 2A group 2 mutation.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2012年第3期169-172,共4页 Chinese Journal of Hematology
基金 国家自然科学基金(30670904)
关键词 血管性血友病因子 突变 血管性血友病 2A型 血管性血友病因子裂解酶 Von Willebrand factor Mutation Von Willebrand disease, type 2A ADAMTS13
  • 相关文献

参考文献8

  • 1Wang Y, Zhang J, Zhang W, et al. A new mutation, Ala1500 Glu, responsible for type 2A yon Willebrand disease. Int J Hema- to1,2000 ,72 :512-516.
  • 2王迎春,张敬宇,万海英,施纪文,李震宇,阮长耿.2A型血管性血友病vWF基因Ala737→Glu的突变[J].中华血液学杂志,1999,20(3):117-119. 被引量:5
  • 3王迎春,张敬宇,万海英,张威,阮长耿.血管性血友病因子Ala737→Glu突变体的构建和表达[J].中华血液学杂志,2000,21(5):256-259. 被引量:1
  • 4Jorieux S, Tuley EA, Gaucher C, et al. The mutation Arg (53)- Trp causes yon Willebrand disease Normandy by abolishing binding to factor W. Studies with recombinant von Willebrand factor. Blood, 1992,79:563-567.
  • 5马珍妮,董宁征,张敬宇,苏健,汪安友,阮长耿.血管性血友病因子裂解蛋白酶的稳定表达及其活性检测[J].生物工程学报,2010,26(2):244-248. 被引量:6
  • 6奚晓东 阮长耿 等.抗血管性假血友病因子单克隆抗体ELISA的建立及其临床应用[J].中华医学检验杂志,1988,11(5):272-272.
  • 7Ginsburg D, Bowie EJ. Molecular genetics of yon Willebrand dis- ease. Blood, 1992, 79:2507-2519.
  • 8Michiels JJ, Gadisseur A, Budde U, et al. Characterization, clas- sification, and treatment of yon Willebrand diseases: a critical ap- praisal of the literature and personal experiences. Semin Thromb Hemost, 2005, 31: 577-601.

二级参考文献14

  • 1Dong JF. Structural and functional correlation of ADAMTS13. Curt Opin Hematol, 2007, 14(3): 270-276.
  • 2Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost, 2008, 99(2): 264-270.
  • 3Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.Hematol Oncol Clin North Am, 2007, 21(4): 609-632.
  • 4Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol, 2008, 3: 249-277.
  • 5Desch KC, Motto DG. Thrombotic thrombocytopenic purpura in humans and mice. Arterioscler Thromb Vasc Biol, 2007, 27(9): 1901-1908.
  • 6Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 2001, 413(6855): 488-494.
  • 7Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med, 2006, 57: 419-436.
  • 8Tao Z, Peny Y, Nolasco L, et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWFstrings by ADAMTS13 under flow conditions. Blood, 2005, 106(13): 4139-4145.
  • 9Zhou W, Tsai HM. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS 13 mutations. Thromb Haemost, 2004, 91(4): 806-811.
  • 10Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 1996, 87(10): 4235-4244.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部